



Uzm. Dr. Oktay Halit AKTEPE

Hacettepe Üniversitesi Tıp Fakültesi'nden (İngilizce) 2010 yılında mezun oldu. 2016 yılında Hacettepe Üniversitesi İç Hastalıkları Anabilim Dalı'nda uzmanlık eğitimini tamamladı. 2017 yılında Sorgun/Yozgat'ta İç Hastalıkları uzmanlığı yaptı. 2020 yılında Tıbbi Onkoloji yandal eğitimini Hacettepe Üniversitesi'nde tamamladı.

ESCI, SCI, SSCI VE AHCI İNDEKSLERİNE GİREN DERGİLERDE YAYINLANAN MAKALELERİ

1. **Aktepe OH**, Guven DC, Sahin TK, Yildirim HC, Celikten B, Yeter HH, et al. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. *Nutr Cancer*. 2021;1-7.
2. **Aktepe OH**, Şahin TK, Güner G, Arik Z, Yalçın Ş. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa B (NF-κB) pathway. *Turk J Med Sci*. 2021;51(1):368-74.
3. **Aktepe OH**, Güner G, Güven DC, Şahin TK, Ardiç FS, Yüce D, et al. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma. *Turk J Med Sci*. 2020.
4. **Aktepe OH**, Güner G, Güven DC, Taban H, Yildirim H, Şahin TK, et al. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. *Turk J Urol*. 2021;47(2):113-9.
5. Sahin TK, **Aktepe OH**, Uckun FM, Yalcin S. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61. *Anticancer Drugs*. 2020;31(6):609-16.
6. Guven DC, Yildirim HC, Bilgin E, **Aktepe OH**, Taban H, Sahin TK, et al. PILE: a candidate prognostic score in cancer patients treated with immunotherapy. *Clin Transl Oncol*. 2021.
7. Guven DC, Sahin TK, **Aktepe OH**, Yildirim HC, Aksoy S, Kilickap S. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19. *Front Oncol*. 2020;10:1553.
8. Guven DC, Sahin TK, Aksun MS, Taban H, **Aktepe OH**, Aksu NM, et al. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. *Support Care Cancer*. 2021;29(4):2029-35.

-
9. Guven DC, Ceylan F, Cakir IY, Cesmececi E, Sayinalp B, Yesilyurt B, et al. Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic. *Support Care Cancer*. 2021.
 10. Guven DC, Aksun MS, Sahin TK, **Aktepe OH**, Yildirim HC, Taban H, et al. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. *Support Care Cancer*. 2021.
 11. Kilickap S, Guven DC, **Aktepe OH**, Aktas BY, Dizdar O. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient. *J Oncol Pharm Pract*. 2020;26(2):496-9.
 12. Guven DC, Guner G, Aktas BY, **Aktepe OH**, Taban H, Arik Z. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design. *Clin Colorectal Cancer*. 2020;19(3):e71-e2.
 13. Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, et al. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study. *J buon*. 2020;25(2):1130-5.
 14. Bas O, Ozbek A, Guven D, **Aktepe O**, Kılıc L, Kertmen N, et al. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma. *J Oncol Pharm Pract*. 2020;26(5):1230-3.